International Stem Cell Corporation (ISCO)
Stock Price Chart
Key Info
| Market Cap | 4.00M |
| Revenue (ttm) | 8.49M |
| Net Income (ttm) | -4.72M |
| Shares Out | 7.54M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 20 |
| Last Price | $0.5300 |
| Previous Close | $0.4913 |
| Change ($) | 0.0387 |
| Change (%) | 7.88% |
| Day's Open | 0.4250 |
| Day's Range | 0.4200 - 0.5300 |
| Day's Volume | 1,148 |
| 52-Week Range | 0.35 - 1.2 |
More Stats
| Market Cap | 4.00M |
| Enterprise Value | 7.34M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 7.54M |
| Float | n/a |
| EPS (basic) | -0.62 |
| EPS (diluted) | -0.63 |
| FCF / Share | -0.08 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | n/a |
| Short Ratio | n/a |
| Short % of Float | n/a |
| Beta | 1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 0.47 |
| PB Ratio | n/a |
| Revenue | 8.49M |
| Operating Income | -4.57M |
| Net Income | -4.72M |
| Free Cash Flow | -610,000 |
| Net Cash | -3.35M |
| Net Cash / Share | -0.44 |
| Gross Margin | 65.25% |
| Operating Margin | -53.82% |
| Profit Margin | -55.50% |
| FCF Margin | -7.18% |
| ROA | -27.54% |
| ROE | -233.00% |
| ROIC | -95.40% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.47 | 11.09 | 7.46 | 7.17 | 7.55 | 7.02 | 6.15 | 4.57 | 4.53 | 1.57 |
| Revenue Growth | -14.58% | 48.73% | 4.06% | -5.11% | 7.61% | 14.15% | 34.6% | 0.77% | 189.03% | - |
| Gross Profit | 5.54 | 7.02 | 5.33 | 5.22 | 5.50 | 5.10 | 4.50 | 3.30 | 2.91 | 0.84 |
| Operating Income | -5.73 | -3.47 | -4.94 | -4.85 | -4.56 | -8.68 | -7.55 | -9.82 | -11.36 | -10.46 |
| Net Income | -4.27 | -2.13 | -6.07 | -1.08 | -2.64 | -12.48 | -10.48 | -9.83 | -9.17 | -12.72 |
| Shares Outstanding | 7.51 | 6.39 | 4.16 | 3.19 | 1.98 | 1.29 | 0.82 | 0.57 | 0.52 | 0.46 |
| Earnings Per Share | -0.57 | -0.33 | -1.46 | -0.34 | -2.26 | -10.34 | -13.49 | -19.49 | -17.99 | -31.48 |
| Operating Cash Flow | -1.40 | -1.08 | -2.14 | -4.20 | -4.12 | -6.42 | -5.64 | -6.69 | -6.96 | -6.95 |
| Capital Expenditures | -0.16 | -0.19 | -0.11 | -0.23 | -0.04 | -0.29 | -0.17 | -0.19 | -0.57 | -0.30 |
| Free Cash Flow | -1.56 | -1.27 | -2.25 | -4.43 | -4.16 | -6.70 | -5.81 | -6.88 | -7.53 | -7.25 |
| Cash & Equivalents | 0.48 | 1.08 | 0.30 | 0.11 | 0.53 | 1.16 | 2.29 | 0.65 | 1.34 | 5.78 |
| Total Debt | 3.46 | 2.05 | - | - | - | - | - | - | - | 0.25 |
| Net Cash / Debt | -2.97 | -0.97 | 0.30 | 0.11 | 0.53 | 1.16 | 2.29 | 0.65 | 1.34 | 5.53 |
| Assets | 6.62 | 7.80 | 6.86 | 7.05 | 7.14 | 7.18 | 7.74 | 5.37 | 5.74 | 9.93 |
| Liabilities | 5.21 | 5.26 | 4.80 | 3.60 | 5.54 | 6.86 | 11.96 | 7.13 | 2.11 | 4.54 |
| Book Value | -2.89 | 2.54 | 2.06 | 3.44 | 1.59 | 0.32 | -4.22 | -1.76 | 3.62 | 5.39 |
Company Profile
Company Details
| Full Name | International Stem Cell Corporation |
| Country | United States |
| Employees | 39 |
| CEO | Andrey Semechkin |
Stock Information
| Ticker Symbol | ISCO |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | OTCMKTS: ISCO |
Description
International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.